Linkster Therapeutics develops precision medicines using translational antibody engineering to ensure targeted delivery to the disease site. Their Flycode platform profiles peptide barcoded antibodies in vitro and in vivo to accelerate pharmacology profiling early in discovery. This technology aims to create next-generation antibody drugs with higher efficacy and reduced off-target effects.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective antibody therapies is challenging because promising in vitro candidates often fail to translate into successful in vivo treatments. This is due to issues such as poor target-organ accumulation and unexpected enrichment in off-target organs, leading to reduced efficacy and potential toxicity. Traditional antibody development methods lack efficient in vivo profiling capabilities early in the discovery process.
Solution
Linkster Therapeutics addresses the translational bottleneck in antibody development with its Flycode® platform, enabling comprehensive in vivo pharmacology profiling. The platform profiles large pools of peptide-barcoded antibodies in vitro, in vivo, and in silico to identify candidates with improved tissue-specific delivery and reduced off-target effects. By integrating advanced targeting strategies and conformation-specific antibody generation, Linkster accelerates the development of precision medicines with enhanced efficacy, better dosing windows, and reduced toxicity. This approach allows for the creation of next-generation antibody drugs tailored to the right target, tissue, and patient.
Target Audience
Linkster Therapeutics primarily targets pharmaceutical companies and research institutions involved in antibody drug discovery and development, seeking to improve the translational success rate of their therapeutic candidates.
Features
- Flycode® platform for high-throughput in vivo pharmacology profiling of antibody candidates
- Peptide-barcoded antibodies for comprehensive assessment of target-organ accumulation and off-target effects
- Advanced targeting strategies for tissue-specific antibody delivery
- Conformation-specific antibody generation against cell surface targets such as GPCRs and SLC transporters
- Translational antibody engineering to optimize efficacy, dosing, and toxicity profiles
- Sybody® platform for generating novel antibody formats